Anwer Habib1, Vinit Karmali1, Michael C John1, Rohini Polavarapu1, Gaku Nakazawa1, Kim Pachura1, Talina Davis1, Frank D Kolodgie1, Renu Virmani2, Aloke V Finn1. 1. From the Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA (A.H., V.K., M.C.J., R.P., K.P., T.D., A.V.F.); and CVPath Institute, Inc, Gaithersburg, MD (G.N., F.D.K., R.V.). 2. From the Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA (A.H., V.K., M.C.J., R.P., K.P., T.D., A.V.F.); and CVPath Institute, Inc, Gaithersburg, MD (G.N., F.D.K., R.V.). avfinn@emory.edu.
Abstract
BACKGROUND: Preclinical evaluation of the vascular response of drug-eluting stents is limited especially in the setting of diabetes mellitus preventing the evaluation of changes in drug-eluting stent design and eluted drugs after clinical use. METHODS AND RESULTS: Cultured human aortic endothelial cells were used to assess the differences between sirolimus and its analog, everolimus, in the setting of hyperglycemia on various cellular functions necessary for endothelial recovery. A diabetic rabbit model of iliac artery stenting was used to compare histological and morphometric characteristics of the vascular response to everolimus-eluting, sirolimus-eluting, and bare metal stent placement. Under hyperglycemic conditions, sirolimus impaired human aortic endothelial cell barrier function, migration, and proliferation to a greater degree compared with everolimus. In our in vivo model of diabetes mellitus, endothelialization at 28 days was significantly lower and endothelial integrity was impaired in sirolimus-eluting stent compared with both everolimus-eluting and bare metal stents. Neointimal area, uncovered struts, and fibrin deposition were significantly higher in sirolimus-eluting compared with everolimus-eluting and bare metal stents. CONCLUSIONS: Use of everolimus-eluting stent results in improved vascular response in our preclinical models of diabetes mellitus.
BACKGROUND: Preclinical evaluation of the vascular response of drug-eluting stents is limited especially in the setting of diabetes mellitus preventing the evaluation of changes in drug-eluting stent design and eluted drugs after clinical use. METHODS AND RESULTS: Cultured human aortic endothelial cells were used to assess the differences between sirolimus and its analog, everolimus, in the setting of hyperglycemia on various cellular functions necessary for endothelial recovery. A diabetic rabbit model of iliac artery stenting was used to compare histological and morphometric characteristics of the vascular response to everolimus-eluting, sirolimus-eluting, and bare metal stent placement. Under hyperglycemic conditions, sirolimus impaired human aortic endothelial cell barrier function, migration, and proliferation to a greater degree compared with everolimus. In our in vivo model of diabetes mellitus, endothelialization at 28 days was significantly lower and endothelial integrity was impaired in sirolimus-eluting stent compared with both everolimus-eluting and bare metal stents. Neointimal area, uncovered struts, and fibrin deposition were significantly higher in sirolimus-eluting compared with everolimus-eluting and bare metal stents. CONCLUSIONS: Use of everolimus-eluting stent results in improved vascular response in our preclinical models of diabetes mellitus.
Authors: Patrick W Serruys; Sigmund Silber; Scot Garg; Robert Jan van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbaek; Adrianus Johannes van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo DiMario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio Bartorelli; Jacintha Ronden; Marco Bressers; Pierre Gobbens; Manuela Negoita; Frank van Leeuwen; Stephan Windecker Journal: N Engl J Med Date: 2010-06-16 Impact factor: 91.245
Authors: Jan-Malte Sinning; Dietrich Baumgart; Nikos Werner; Volker Klauss; Frank M Baer; Franz Hartmann; Helmut Drexler; Wolfgang Motz; Heinrich Klues; Wolfram Voelker; Thomas Pfannebecker; Hans-Peter Stoll; Georg Nickenig Journal: Am Heart J Date: 2012-03 Impact factor: 4.749
Authors: Gregg W Stone; Elvin Kedhi; Dean J Kereiakes; Helen Parise; Martin Fahy; Patrick W Serruys; Pieter C Smits Journal: Circulation Date: 2011-08-08 Impact factor: 29.690
Authors: Gaku Nakazawa; Fumiyuki Otsuka; Masataka Nakano; Marc Vorpahl; Saami K Yazdani; Elena Ladich; Frank D Kolodgie; Aloke V Finn; Renu Virmani Journal: J Am Coll Cardiol Date: 2011-03-15 Impact factor: 24.094
Authors: Damir Hamamdzic; Robert S Fenning; Dhavalkumar Patel; Emile R Mohler; Ksenia A Orlova; Alexander C Wright; Raul Llano; Martin G Keane; Richard P Shannon; Morris J Birnbaum; Robert L Wilensky Journal: Am J Physiol Heart Circ Physiol Date: 2010-07-02 Impact factor: 4.733
Authors: Michael C John; Rainer Wessely; Adnan Kastrati; Albert Schömig; Michael Joner; Mayu Uchihashi; Johanna Crimins; Scott Lajoie; Frank D Kolodgie; Herman K Gold; Renu Virmani; Aloke V Finn Journal: JACC Cardiovasc Interv Date: 2008-10 Impact factor: 11.195